| 1 |
Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005;5:309-16.
DOI
|
| 2 |
Trends in safety information reporting including medicines 2015 [Internet]. Anyang (Korea): Korea Institute of Drug Safety & Risk Management; 2015 [cited 2019 Jun 28]. Available from: https://www.drugsafe.or.kr/iwt/ds/ko/bbs/EgovBbs.do?bbsId=BBSMSTR_000000000021&nttId=1905&pageIndex=1&searchCnd=&searchWrd=.
|
| 3 |
Jang GC, Lim HS, Lee CJ. Epidemiology of pediatric adverse drug reactions in Korea: using big data of 48.1 million south Korean health-care records and Korea adverse event reporting system database. In:300European Academy of Allergy and Clinical Immunology Congress; 2017 Jun 17-21; Helsinki, Finland.
|
| 4 |
Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 2017;88:78-86.
DOI
|
| 5 |
Moon J, Kim TJ, Lim JA, Sunwoo JS, Byun JI, Lee ST, et al. HLA- B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption. Epilepsia 2016;57:1879-86.
DOI
|
| 6 |
Verrotti A, Scaparrotta A, Grosso S, Chiarelli F, Coppola G. Anticonvulsant drugs and hematological disease. Neurol Sci 2014;35:983-93.
DOI
|
| 7 |
Tecoma ES. Oxcarbazepine. Epilepsia 1999;40 Suppl 5:S37-46.
DOI
|
| 8 |
Mahmud J, Mathews M, Verma S, Basil B. Oxcarbazepine-induced thrombocytopenia. Psychosomatics 2006;47:73-4.
DOI
|
| 9 |
Calamaras MR, Stowe ZN, Newport DJ. Pancytopenia associated with the introduction of oxcarbazepine. J Clin Psychopharmacol 2007;27: 217-8.
DOI
|
| 10 |
Jung GH, You SJ. Evaluation of hematologic profile may be needed for patients treated with oxcarbazepine. Korean J Pediatr 2019;62: 312-6.
DOI
|
webmaster
